Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
C 4.86 -3.57% -0.18
MRSN closed down 3.57 percent on Monday, March 18, 2024, on 1.69 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Hammer Candlestick Bullish 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Support Bullish -3.57%
Pocket Pivot Bullish Swing Setup -3.57%
Volume Surge Other -3.57%
NR7 Range Contraction -3.57%
Wide Bands Range Expansion -3.57%
MACD Bearish Signal Line Cross Bearish -2.90%
Wide Bands Range Expansion -2.90%

   Recent Intraday Alerts

Alert Time
1.5x Volume Pace about 18 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Down 2 % about 18 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mersana Therapeutics, Inc. Description

Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Immunology Clinical Development Monoclonal Antibodies Chemotherapy Antibody Drug Conjugate Synaffix

Is MRSN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.62
52 Week Low 0.8014
Average Volume 2,482,924
200-Day Moving Average 2.75
50-Day Moving Average 3.98
20-Day Moving Average 5.02
10-Day Moving Average 5.51
Average True Range 0.47
RSI (14) 51.46
ADX 54.29
+DI 23.67
-DI 18.41
Chandelier Exit (Long, 3 ATRs) 4.86
Chandelier Exit (Short, 3 ATRs) 4.96
Upper Bollinger Bands 6.66
Lower Bollinger Band 3.37
Percent B (%b) 0.45
BandWidth 65.63
MACD Line 0.42
MACD Signal Line 0.54
MACD Histogram -0.1243
Fundamentals Value
Market Cap 586.03 Million
Num Shares 121 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -2.76
Price-to-Sales 12.79
Price-to-Book 8.96
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.60
Resistance 3 (R3) 5.57 5.31 5.47
Resistance 2 (R2) 5.31 5.12 5.32 5.43
Resistance 1 (R1) 5.08 5.00 4.95 5.11 5.39
Pivot Point 4.82 4.82 4.75 4.83 4.82
Support 1 (S1) 4.59 4.63 4.46 4.62 4.33
Support 2 (S2) 4.33 4.51 4.34 4.29
Support 3 (S3) 4.10 4.33 4.25
Support 4 (S4) 4.13